纽维克蒂斯制药

最新新闻

• 评级变动
  H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2026/6/13
• Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $33
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  Lucid Capital Initiates Nuvectis Pharma(NVCT.US) With Buy Rating, Announces Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2025/2/26
• 评级变动
  Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/6/23
• 评级变动
  Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  Maxim Group Initiates Nuvectis Pharma(NVCT.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2025/4/3
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB)
  TipRanks · 2026/2/12
• 评级变动
  H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $39
  \u5e02\u573a\u8d44\u8baf · 2026/6/22
• 评级变动
  Laidlaw Initiates Nuvectis Pharma(NVCT.US) With Buy Rating, Announces Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2025/3/18
• 评级变动
  H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/5/5
• 评级变动
  Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $30
  \u5e02\u573a\u8d44\u8baf · 2026/6/24
• 评级变动
  Roth MKM Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2025/7/10
• H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2025/5/1
• 评级变动
  H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Cuts Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2025/8/4
• Lucid Capital Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Raises Target Price to $34
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 评级变动
  H.C. Wainwright Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $13
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• Cantor Fitzgerald Initiates Nuvectis Pharma(NVCT.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/24
• Maxim Group Maintains Nuvectis Pharma(NVCT.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/9/26

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。